Second-line treatments, known as device-aided therapies (DATs), have been developed for LDRCs, such as continuous subcutaneous apomorphine infusion (CSAI), continuous subcutaneous foslevodopafoscarbidopa, infusion of levodopacarbidopa intestinal gel (LCIG entacapone) and subthalamic deep brain stimulation
Sterile water has no bacteriostatic preservative
Collagen organization and cross-linking, which determine the ultimate strength and resilience of repaired tissue, develop over 6 to 12 weeks or longer
Until then, I will continue recommending treatments that have: Human outcome data Clear dosing standards Defined safety profiles Transparent regulatory oversight In sports medicine, the goal is not just faster healing
Rotate sites systematically and document each administration [15]